Anti-Complement C3a/C3a(desArg)/C3 Antibody (K13/16-5.7)
Our mouse Complement C3a/C3a(desArg)/C3 monoclonal antibody from Antibodies Incorporated is produced in-house from clone K13/16-5.7. It detects human Complement C3a/C3a(desArg)/C3 and is Protein A or Protein G purified. Works in ELISA, IF, IHC, WB.
Immunohistochemistry detection of Complement C3a/C3a/(desArg)/C3 in human kidney tissue using Anti-Complement C3a/C3a(desArg)/C3 Antibody (Cat. GAU 013-16-010). Tissue was mounted and pariffin fixed. Heat induced antigen retrieval was performed using citrate buffer, heated, and then blocked. After washing, the primary antibody (Cat. GAU 013-16-010) was incubated with the sample at a dilution of 1:150. Strong staining of veins of nephritis kidney was seen.
Click on image to zoom
SKU: GAU 013-16-010
Ships: 1-2 business days
Product Details
Complement C3a/C3a(desArg)/C3
Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).
Protein A or Protein G purified
1 mg/mL ±15%
Monoclonal
K13/16-5.7
IgG1/k
ELISA, IF, IHC, WB
Mouse
C3
Human C3a
Human
Human
2-8°C without exposure to light
Liquid
BSA free
0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
IHC: 1:150
GAU 013-16 can be used as a capture antibody in sandwich ELISA with GAU 017-01 as a biotinylated detection antibody. (4, 5) GAU 013-16 can also be used to immunopurify C3a (3). GAU 013-16 effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay. (2) GAU 013-16 was used in IHC in formaline fixed paraffin embedded tissue with a dilution of 1:150. GAU 103-16 was used in IF with a dilution of 1:75.
Unconjugated
GAU 013-16 is specific for human C3, C3a and C3a (desArg) (1) and does not cross-react with C4a or C5a. (2, 3) GAU 013-16 recognizes a different epitope on the 9 kDa C3a than GAU 017-01 (2, 3). No reaction is seen with a synthetic octapeptide representing the C3a C-terminal. (2)
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
United States
24 months from date of receipt
C3; CPAMD1; Complement C3; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; Cleaved into: Complement C3 beta chain; C3-beta-c; C3bc; Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein; ASP; C3adesArg; Complement C3b; Complement C3b-alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2; AHUS5; ARMD9; C3a; C3b; HEL-S-62p; acylation-stimulating protein cleavage product; complement component 3; complement component C3a; complement component C3b; epididymis secretory sperm binding protein Li 62p; prepro-C3
Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. {ECO:0000269|PubMed:12878586, ECO:0000269|PubMed:18204047, ECO:0000269|PubMed:28264884, ECO:0000269|PubMed:31507604, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:624565, ECO:0000269|PubMed:6554279}.; [Complement C3b]: Non-enzymatic component of C5 convertase (PubMed:28264884, PubMed:31507604, PubMed:3653927, PubMed:3897448). Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that marks the surface of antigens for removal (PubMed:28264884, PubMed:31507604, PubMed:3653927, PubMed:3897448, PubMed:833545, PubMed:8349625). Complement C3b binds covalently via its reactive thioester, to cell surface carbohydrates or immune aggregates (PubMed:6903192). Together with complement C4b, it then recruits the serine protease complement C2b to form the C5 convertase, which cleaves and activate C5, the next component of the complement pathways (PubMed:12878586, PubMed:18204047, PubMed:2387864). In the alternative complement pathway, recruits the serine protease CFB to form the C5 convertase that cleaves and activates C5 (PubMed:624565, PubMed:6554279). {ECO:0000269|PubMed:12878586, ECO:0000269|PubMed:18204047, ECO:0000269|PubMed:2387864, ECO:0000269|PubMed:28264884, ECO:0000269|PubMed:31507604, ECO:0000269|PubMed:3653927, ECO:0000269|PubMed:3897448, ECO:0000269|PubMed:624565, ECO:0000269|PubMed:6554279, ECO:0000269|PubMed:6903192, ECO:0000269|PubMed:833545, ECO:0000269|PubMed:8349625}.; [C3a anaphylatoxin]: Mediator of local inflammatory process released following cleavage by C3 convertase (PubMed:6968751, PubMed:37169960, PubMed:37852260). Acts by binding to its receptor, C3AR1, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C3AR1 (PubMed:8702752, PubMed:37169960, PubMed:37852260). C3a anaphylatoxin stimulates the activation of immune cells such as mast cells and basophilic leukocytes to release inflammation agents, such as cytokines, chemokines and histamine, which promote inflammation development (PubMed:23383423). Also acts as potent chemoattractant for the migration of macrophages and neutrophils to the inflamed tissues, resulting in neutralization of the inflammatory triggers by multiple ways, such as phagocytosis and generation of reactive oxidants (PubMed:23383423, PubMed:342601, PubMed:5778786). {ECO:0000269|PubMed:342601, ECO:0000269|PubMed:37169960, ECO:0000269|PubMed:37852260, ECO:0000269|PubMed:5778786, ECO:0000269|PubMed:6968751, ECO:0000269|PubMed:8702752, ECO:0000303|PubMed:23383423}.; [Acylation stimulating protein]: Adipogenic hormone that stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance (PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750, PubMed:2909530, PubMed:8376604, PubMed:9059512). Appears to stimulate triglyceride synthesis via activation of the PLC, MAPK and AKT signaling pathways (PubMed:16333141). Acts by binding to its receptor, C5AR2, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C5AR2 (PubMed:11773063, PubMed:12540846, PubMed:19615750). In contrast to C3a anaphylatoxin peptide, does not show pro-inflammatory activity (PubMed:37852260). {ECO:0000269|PubMed:10432298, ECO:0000269|PubMed:11773063, ECO:0000269|PubMed:12540846, ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:16333141, ECO:0000269|PubMed:19615750, ECO:0000269|PubMed:2909530, ECO:0000269|PubMed:37852260, ECO:0000269|PubMed:8376604, ECO:0000269|PubMed:9059512}.; [C3-beta-c]: Acts as a chemoattractant for neutrophils in chronic inflammation. {ECO:0000250|UniProtKB:P01026}.
718
Shipped on ice packs

